1. Introduction {#sec1-jcm-09-00514}
===============

*Pseudomonas aeruginosa* is one of the most difficult-to-treat microorganisms due to its intrinsic resistance profile and its extraordinary ability to develop additional resistance through selection of chromosomal mutations and acquisition of resistance genes \[[@B1-jcm-09-00514],[@B2-jcm-09-00514]\]. In recent years, the emergence of high-risk clones that select multidrug- (MDR) or extensively drug-resistant (XDR) strains widely disseminated in hospitals throughout the world is also a factor of concern \[[@B2-jcm-09-00514],[@B3-jcm-09-00514],[@B4-jcm-09-00514]\]. The increase in MDR/XDR strains seriously compromises antibiotic treatment options and consequently the probability of receiving appropriate early antimicrobial drugs, which may lead to poor outcomes, particularly in the presence of severe infections \[[@B5-jcm-09-00514],[@B6-jcm-09-00514],[@B7-jcm-09-00514]\].

*P. aeruginosa* has an extraordinary capacity for causing a wide range of infections. Bloodstream infection (BSI) is considered one of its most serious and dreaded complications, with a reported mortality ranging from 18% to 61% \[[@B8-jcm-09-00514]\]. It has been hypothesized that BSIs caused by antimicrobial-resistant strains lead to worse outcomes than those caused by susceptible ones, although controversial findings have been reported over the years \[[@B9-jcm-09-00514],[@B10-jcm-09-00514],[@B11-jcm-09-00514],[@B12-jcm-09-00514],[@B13-jcm-09-00514],[@B14-jcm-09-00514],[@B15-jcm-09-00514],[@B16-jcm-09-00514]\]. These conflicting results could partly be due to the difficulty of elucidating the influence of other factors on outcomes, such as underlying conditions, infectious syndrome severity, source of infection, therapeutic management, or bacterial virulence determinants \[[@B9-jcm-09-00514],[@B10-jcm-09-00514],[@B11-jcm-09-00514],[@B12-jcm-09-00514],[@B13-jcm-09-00514],[@B14-jcm-09-00514],[@B15-jcm-09-00514],[@B16-jcm-09-00514],[@B17-jcm-09-00514]\]. Those studies have some limitations: some results were obtained before Magiorakos et al. \[[@B5-jcm-09-00514]\] standardized the terminology, or included different sources of infection, or were limited by insufficient sample sizes, and reliable conclusions could not be drawn. Furthermore, most were focused only on carbapenem-resistant or MDR *P. aeruginosa* strains, but not specifically on XDR isolates, which have only few active drugs available and are more prone to be linked to high-risk clones. In line with this, previous studies showed that almost all XDR isolates analyzed at our institution belonged to well-described *P. aeruginosa* high-risk clones, with sequence type 175 (ST175) being by far the most frequent high-risk clone observed \[[@B18-jcm-09-00514],[@B19-jcm-09-00514],[@B20-jcm-09-00514],[@B21-jcm-09-00514]\]. Unpublished local data also showed that 85% of our XDR *P. aeruginosa* isolates were clonally related, showing an endemic situation at our center.

Hence, we present a retrospective analysis of a large cohort of *P. aeruginosa* bacteremia designed to assess the impact of XDR phenotype on mortality.

2. Methods {#sec2-jcm-09-00514}
==========

2.1. Hospital Setting, Study Design, and Participants {#sec2dot1-jcm-09-00514}
-----------------------------------------------------

The study was conducted at the Hospital del Mar, a 420-bed tertiary-care university hospital in Barcelona, Spain. We performed a retrospective analysis of all patients aged ≥ 18 years old that had been prospectively recorded with positive blood cultures for *P. aeruginosa* from January 2000 to December 2018. Positive blood cultures were reported daily by the Microbiology Department. Patients were followed for up to 30 days from the onset of BSI to assess 14- and 30-day all-cause mortality. Only the first episode of bacteremia per each patient was considered. Polymicrobial BSIs were excluded.

The study was approved by the Clinical Research Ethics Committee of Parc de Salut (register no. 2019/8758I). The need for written informed consent was waived due to the observational nature of the study and retrospective analysis.

2.2. Study Objectives and Outcomes {#sec2dot2-jcm-09-00514}
----------------------------------

We aimed to assess the impact of XDR phenotype on patients with *P. aeruginosa* bacteremia. The main outcomes were mortality at 14 and 30 days after the onset of bacteremia. An additional subanalysis was performed involving only the patients with high-risk sources of infection.

2.3. Variables and Data Source {#sec2dot3-jcm-09-00514}
------------------------------

Trained study investigators collected demographic, clinical, and microbiological data from the hospital or primary care electronic medical charts and the microbiology laboratory database, including the following: sex, age, underlying diseases, site of acquisition, source of infection, severity of BSI, antibiotic treatment, BSI microbiological resistance profile, and 14- and 30-day all-cause mortality. Follow-up information for up to 30 days after the onset of bacteremia was obtained by reviewing electronic medical charts.

2.4. Microbiological Studies {#sec2dot4-jcm-09-00514}
----------------------------

Bacterial growth in blood cultures was detected by the BacT/Alert^®^ System (bioMérieux, Marcy l'Etoile, France). Bacterial identification was performed by standard biochemical tests and by MALDI-TOF since 2014. Antibiotic susceptibility testing was routinely performed by two dilution-based methods in two different periods due to changes in the laboratory workflow: broth microdilution panels MicroScan^®^ using the WalkAway^®^ system (Beckman Coulter, Brea, California, United States) from 2000 to 2008, and AST cards using the VITEK^®^2 System (bioMérieux, Marcy l'Etoile, France) from then on. Antimicrobials tested were the following: ciprofloxacin, piperacillin-tazobactam, ceftazidime, cefepime, imipenem, meropenem, aztreonam, gentamicin, tobramycin, amikacin. and colistin. Antimicrobial susceptibility testing results were categorized according to the Clinical and Laboratory Standards Institute (CLSI) until 2013, and thenceforth according to the European Committee on Antimicrobial Susceptibility Testing (EUCAST). Isolates categorized as intermediate were considered as resistant.

*P. aeruginosa* isolates were classified as XDR when they were non-susceptible to at least one agent in all but two or fewer antipseudomonal antimicrobial categories, and as MDR when they were non-susceptible to at least one agent in three or more antipseudomonal antimicrobial categories \[[@B5-jcm-09-00514]\]. Those strains that did not meet the previous criteria were classified as non-MDR *P. aeruginosa*. Both non-MDR and MDR isolates were included in the non-XDR group.

Clonality and antibiotic resistance mechanisms were not investigated specifically for this study, but some strains had been analyzed by our group before \[[@B18-jcm-09-00514],[@B20-jcm-09-00514],[@B21-jcm-09-00514]\]. As previously reported in detail, clonal relatedness of XDR *P. aeruginosa* isolates was analyzed using pulsed-field gel electrophoresis, multilocus sequence typing, and whole-genome sequencing. Regarding resistant mechanisms, overexpression of chromosomal β-lactamase AmpC or efflux pumps, OprD deficiency, or horizontal acquired enzymes were investigated, among others \[[@B18-jcm-09-00514],[@B20-jcm-09-00514],[@B21-jcm-09-00514]\].

2.5. Definitions {#sec2dot5-jcm-09-00514}
----------------

*P. aeruginosa* bacteremia was defined as at least one positive blood culture obtained from a patient with signs and symptoms of infection.

Presence of comorbidities and severity of underlying diseases were assessed by the Charlson comorbidity index \[[@B22-jcm-09-00514]\] and McCabe score \[[@B23-jcm-09-00514]\]. Neutropenia was defined as an absolute neutrophil count of ≤500 cells/mm^3^. Site of acquisition was defined according to the classification by Friedman et al. \[[@B24-jcm-09-00514]\]. BSIs that did not meet the nosocomial or healthcare-associated criteria were considered as of community acquisition. BSI severity was evaluated by Pitt score \[[@B25-jcm-09-00514]\], the need of intensive care unit admission, and the presence of septic shock, defined as the need for vasopressors to maintain a mean arterial pressure of at least 65 mmHg \[[@B26-jcm-09-00514]\]. Source of infection was defined as the most likely origin of infection responsible for the BSI according to medical records. Catheter-related bloodstream infection, urinary tract infection, respiratory tract infection, skin and soft tissue infection, intraabdominal infection, and other sources (including endocarditis, otorhinolaryngologic, central nervous system, and surgical site sources) were included. When the origin of the infection was unclear, it was defined as BSI of unknown origin. For risk of mortality \[[@B10-jcm-09-00514]\], sources of infection were divided into two groups: (a) low-risk sources or those involving either catheter-related bloodstream infections or urinary tract infections and (b) high-risk sources or those involving others.

Appropriate empiric antibiotic therapy was considered when at least 1 antipseudomonal antibiotic with in vitro activity was administered during the first 24 h after taking the blood cultures, whereas appropriate definite antibiotic therapy refers to the moment of knowing bacteria susceptibility results. When pneumonia was the source of infection, aminoglycoside monotherapy was considered an inadequate treatment \[[@B27-jcm-09-00514]\]. Combination therapy was defined as two antipseudomonal drugs used for at least 24 h.

2.6. Statistical Analysis {#sec2dot6-jcm-09-00514}
-------------------------

Continuous quantitative variables were presented as median and interquartile range (IQR). For categorical variables, number of cases and percentages were used. The Student's *t*-test or Mann--Whitney U test were applied to compare continuous variables, and Fisher's exact test or Pearson's χ^2^ test to contrast categorical variables, as appropriate. The Cox proportional hazards model was used to explore 14- and 30-day mortality events. Univariate and multivariate survival analyses were performed, and results were reported as the hazard ratio (HR) and 95% confidence interval (CI). The proportional hazard assumption checked by examining Schoenfeld residuals (for overall model and variable-by-variable) was not violated. The variables introduced into the multivariate analysis included those with a crude *p* value ≤ 0.1 in the univariate analysis or those considered clinically relevant for the outcome and the study hypothesis. The explained criteria are based on backward selection but controlling by clinical significance. All *p*-values were two-tailed and statistical significance was \<0.05. Statistical analyses were performed using STATA 15.1.

3. Results {#sec3-jcm-09-00514}
==========

A total of 506 episodes of *P. aeruginosa* bacteremia were assessed during the study period. Of these, 124 were excluded: 114 had polymicrobial bacteremia, 9 patients presented more than one episode of *P. aeruginosa* BSI, and another was lost to follow-up. Therefore, 382 patients were finally recorded, and 122 (31.9%) of these episodes corresponded to XDR *P. aeruginosa* ([Figure 1](#jcm-09-00514-f001){ref-type="fig"}). In the non-XDR group, 35/260 (13.5%) were MDR and 225/260 (86.5%) non-MDR strains.

The rate of antimicrobial susceptibility of the total cohort and according to XDR pattern are shown in [Figure 2](#jcm-09-00514-f002){ref-type="fig"}. With respect to the XDR antimicrobial susceptibility profile, the most common pattern observed was non-susceptibility to all antipseudomonal agents except colistin (98.4%, *n* = 120/122) and amikacin (89.3%, *n* = 109/122).

Demographics and clinical characteristics of the total cohort and according to XDR pattern are shown in [Table 1](#jcm-09-00514-t001){ref-type="table"}. Compared to patients with non-XDR *P. aeruginosa* bacteremia, those with XDR *P. aeruginosa* were more likely to have a low-risk source of bacteremia (50.8% vs. 35.8%, *p* = 0.005), but a higher Pitt score (median points, 2 (IQR 1 to 4) vs. 2 (IQR 0 to 3); *p* = 0.017). Among patients with XDR bacteremia, the following significant differences were also observed when compared with non-XDR BSI episodes: history of hematologic malignancy (22.1% vs. 11.9%; *p* = 0.01), nosocomial acquisition (82.8% vs. 55%; *p* \< 0.001), receiving inappropriate empirical antibiotic therapy (88.5% vs. 42.3%; *p* \< 0.001), and use of combined antimicrobial therapy (51.6% vs. 33.5%; *p* \< 0.001).

3.1. Mortality and Risk Factors for Mortality {#sec3dot1-jcm-09-00514}
---------------------------------------------

The 14-day all-cause mortality rate for all patients was 23.3% (89/382), whereas at day 30, it was 30.9% (118/382). No statistically significant differences in mortality rates were found between XDR and non-XDR *P. aeruginosa* groups at either day 14 or day 30.

Multivariate analysis using a Cox proportional hazards model, adjusted for sex and age, showed that the independent risk factors for 14-day all-cause mortality were as follows: a high-risk source of bacteremia (HR 3.07, 95% CI, 1.73 to 5.46; *p* \< 0.001), presentation with septic shock (HR 1.75, 95% CI, 1.12 to 2.75; *p* = 0.015), and higher Pitt scores (one-point increments; HR 1.25, 95% CI, 1.12 to 1.38; *p* \< 0.001). Receiving appropriate definitive antimicrobial therapy was a protective factor (HR 0.39, 95% CI, 0.24 to 0.62; *p* \< 0.001). XDR *P. aeruginosa* BSI was not related to 14-day mortality (HR, 1.07; 95% CI, 0.68 to 1.67; *p* = 0.777) ([Table 2](#jcm-09-00514-t002){ref-type="table"}).

Regarding 30-day mortality, the independent risk factors for mortality observed in a Cox proportional hazards model, adjusted for sex and age, were as follows: a high-risk source of infection (HR 2.49, 95% CI, 1.56 to 3.99; *p* \< 0.001), septic shock (HR 1.77, 95% CI, 1.18 to 2.65; *p* = 0.006), and Pitt scores (one-point increments; HR 1.25, 95% CI, 1.13 to 1.37; *p* \< 0.001), whereas appropriate definitive therapy (HR 0.42, 95% CI, 0.27 to 0.66; *p* \< 0.001) was identified as a protective factor. XDR *P. aeruginosa* BSI was not related to 30-day mortality (HR 1.14, 95% CI, 0.77 to 1.69; *p* = 0.504) ([Table 3](#jcm-09-00514-t003){ref-type="table"}).

3.2. Subanalysis {#sec3dot2-jcm-09-00514}
----------------

Because the XDR group more frequently had a low-risk source of bacteremia, an additional analysis was performed that considered only high-risk sources of BSI ([Table S1, Supplementary Materials](#app1-jcm-09-00514){ref-type="app"}). In multivariate analysis, factors independently associated with 14- and 30-day all-cause mortality were once again Pitt score, septic shock, and inappropriate definitive antibiotic therapy. In addition, at day 14, combined antimicrobial therapy was identified as a protective factor for mortality (HR 0.56, 95% CI 0.33 to 0.93; *p* = 0.027) ([Tables S2 and S3, Supplementary Materials](#app1-jcm-09-00514){ref-type="app"}).

4. Discussion {#sec4-jcm-09-00514}
=============

Multiple reports have drawn attention to the worryingly high rates of XDR *P. aeruginosa* infections worldwide \[[@B1-jcm-09-00514],[@B2-jcm-09-00514],[@B28-jcm-09-00514],[@B29-jcm-09-00514]\]. Although previous studies have assessed the impact on the outcome of carbapenem-resistant or MDR *P. aeruginosa* BSI \[[@B9-jcm-09-00514],[@B10-jcm-09-00514],[@B11-jcm-09-00514],[@B12-jcm-09-00514],[@B13-jcm-09-00514],[@B14-jcm-09-00514],[@B15-jcm-09-00514],[@B16-jcm-09-00514]\], little is known about the role of XDR strains. In order to obtain a better understanding of this issue, we present here the results of the largest cohort of patients with monomicrobial XDR *P. aeruginosa* bacteremia published to date.

Our data show that the vast majority of XDR *P. aeruginosa* strains were non-susceptible to all antipseudomonal agents apart from colistin and amikacin. Although clonality and the resistance mechanisms of the isolates were not specifically investigated in this study, previous ones found that, in XDR *P. aeruginosa* strains, the ST175 high-risk clone was by far the most frequent at our site \[[@B18-jcm-09-00514],[@B19-jcm-09-00514],[@B20-jcm-09-00514],[@B21-jcm-09-00514]\]. In a Spanish multicenter study by our group (COLIMERO study) \[[@B18-jcm-09-00514]\], 17/21 (81%) strains included from our center belonged to the ST175 high-risk clone. In another recent survey of *P. aeruginosa* molecular epidemiology and antimicrobial resistance in Spain, del Barrio-Tofiño et al. \[[@B19-jcm-09-00514]\] found that all isolates recovered from our site also belonged to the ST175 high-risk clone. In these two previous reports \[[@B18-jcm-09-00514],[@B19-jcm-09-00514]\], the underlying resistance mechanisms in the XDR phenotype were mainly a combination of chromosomal mutations such as hyperproduction of chromosomal AmpC β-lactamases, efflux pumps, OprD deficiency and/or quinolone resistance-determining region mutations, rather than horizontally acquired carbapenemases.

Our study showed that the all-cause mortality rate for patients with XDR *P. aeruginosa* bacteremia at day 30 was above 30%, which is similar to results reported in previous series of carbapenem-resistant or MDR isolates \[[@B9-jcm-09-00514],[@B10-jcm-09-00514],[@B13-jcm-09-00514],[@B16-jcm-09-00514],[@B17-jcm-09-00514],[@B30-jcm-09-00514]\]. We observed that severity at presentation or a high-risk source of *P. aeruginosa* bacteremia were independent predictors of mortality, as has been previously reported \[[@B9-jcm-09-00514],[@B10-jcm-09-00514],[@B12-jcm-09-00514],[@B14-jcm-09-00514],[@B15-jcm-09-00514],[@B16-jcm-09-00514]\]. On the other hand, although it is often assumed that antibiotic-resistant *P. aeruginosa* bacteremia results in worse outcomes, our study found that an XDR profile was not associated with higher mortality rates, even after considering only high-risk source BSI. Conflicting results have been reported for carbapenem-resistant or MDR *P. aeruginosa* infections \[[@B9-jcm-09-00514],[@B10-jcm-09-00514],[@B11-jcm-09-00514],[@B12-jcm-09-00514],[@B13-jcm-09-00514],[@B14-jcm-09-00514],[@B15-jcm-09-00514],[@B16-jcm-09-00514]\]. In the case of XDR isolates, the evidence is even scarcer and there are only a few published studies. Recio et al. \[[@B31-jcm-09-00514]\] also failed to identify the XDR phenotype as a predictor of mortality in a cohort of 70 patients with *P. aeruginosa* bacteremia in Spain that included 24 XDR strains (10 of them belonging to the ST175 high-risk clone and 11 to ST235). Another study carried out in Brazil \[[@B11-jcm-09-00514]\] did not find an association in 120 patients with *P. aeruginosa* bacteremia, 31 of them XDR strains. On the other hand, a recent study of a cohort of 243 patients, including 87 XDR isolates (43 strains linked to ST175 high-risk clone and 33 to ST235) \[[@B16-jcm-09-00514]\] found MDR phenotype as an independent predictor of 30-day crude mortality. In line with this, a recent Spanish study aimed at assessing the impact of virulence on the outcome of *P. aeruginosa* BSI \[[@B32-jcm-09-00514]\] also found that XDR phenotype was statistically linked to 30-day mortality in a cohort of 593 bacteremia cases, 81 of them XDR isolates (61 ST175, 9 ST111, 2 ST235, and 2 ST244), although multivariate analysis data were not provided. Another Spanish study \[[@B33-jcm-09-00514]\] focused on BSIs in solid organ transplant recipients identified a higher mortality rate for patients with bacteremia due to XDR *P. aeruginosa* (*n* = 31) compared to those with BSI caused by other microorganisms (*n* = 287), and it was found to be an independent risk factor for mortality (20/22 studied strains showed the ST175 pattern). Other studies \[[@B34-jcm-09-00514],[@B35-jcm-09-00514]\] have addressed the impact of XDR strains on different sources of infection, not exclusively in bacteremia. For instance, a Thai study of 255 patients with *P. aeruginosa* infections, including 56 XDR strains, found that an XDR phenotype was an independent factor of mortality attributable to infection when compared to non-XDR isolates \[[@B34-jcm-09-00514]\]. Samonis et al. found the same association with mortality in a cohort of 89 *P. aeruginosa* infections (52 of them with bacteremia and 22 XDR isolates) in cancer patients in Greece \[[@B35-jcm-09-00514]\].

As was the case for carbapenem-resistant or MDR *P. aeruginosa* bacteremia, conflicting findings are also reported for XDR strains, suggesting that the prognosis of BSI depends on several factors apart from the resistance phenotype. In our study, no relevant differences were observed between the two groups either for preexisting comorbidities or severity of clinical presentation at the onset of bacteremia, although a low-risk source of bacteremia was more frequently observed in the XDR group. This finding could partially explain the lack of association between XDR phenotype and mortality, although the same results were obtained after adjusting for source of infection, which rules out this hypothesis. In addition, although patients with an XDR *P. aeruginosa* BSI have a higher probability of receiving inadequate empirical antimicrobial therapy, unexpectedly, this was not associated with worse outcomes. Some authors argue that in cases of *P. aeruginosa* bacteremia, a 48--72 h delay before receiving appropriate antibiotics may not be so crucial to patient outcome, since mortality is mainly due to other factors, such as severity of infection, having a high-risk source, or receiving inappropriate definitive antibiotic therapy \[[@B10-jcm-09-00514],[@B12-jcm-09-00514],[@B15-jcm-09-00514],[@B36-jcm-09-00514],[@B37-jcm-09-00514]\], which is consistent with the results of the present study.

Another hypothesis to explain the lack of impact of XDR phenotype on mortality could be the influence of the acquisition of resistance mechanisms. It has been hypothesized that it may involve a fitness cost resulting in strains with lower virulence, and with a reduced inflammatory response in the host when compared to susceptible isolates \[[@B38-jcm-09-00514],[@B39-jcm-09-00514],[@B40-jcm-09-00514],[@B41-jcm-09-00514]\]. On the other hand, it has also been reported that not all resistance mutations lead to a biological cost such as the OprD deficiency \[[@B42-jcm-09-00514]\]. Indeed, some studies have identified that MDR strains can develop compensatory or suppressor mechanisms that allow them to recover their baseline fitness \[[@B12-jcm-09-00514],[@B43-jcm-09-00514],[@B44-jcm-09-00514]\]. Other studies have found that some high-risk clones can be as virulent as susceptible strains, despite exhibiting many resistance mutations, suggesting that pathogenicity depends not only on the fitness cost of resistance, but also on the presence of certain virulence determinants such as exoU-positive genotype or O11 antigen serotype \[[@B16-jcm-09-00514],[@B17-jcm-09-00514],[@B31-jcm-09-00514],[@B32-jcm-09-00514]\]. The ST235 high-risk clone, for example, appears to be particularly virulent in cases of ExoU production, whereas the virulence of ST175, the most prevalent high-risk clone observed at our institution, is especially low \[[@B16-jcm-09-00514],[@B17-jcm-09-00514],[@B31-jcm-09-00514],[@B32-jcm-09-00514]\]. Thus, it may be inferred that the high prevalence of the less virulent ST175 high-risk clone at our institution may account in part for the lack of detrimental impact on mortality of the XDR phenotype.

One of the most interesting findings of our study is that combined antimicrobial therapy improves prognosis at day 14 in high-risk source bacteremia. Previous studies have addressed this issue \[[@B45-jcm-09-00514],[@B46-jcm-09-00514],[@B47-jcm-09-00514],[@B48-jcm-09-00514],[@B49-jcm-09-00514]\], although they were not focused specifically on XDR *P. aeruginosa* bacteremia. Some of these \[[@B46-jcm-09-00514],[@B47-jcm-09-00514],[@B48-jcm-09-00514]\] also found a protective effect for patients receiving two active drugs for high-risk sources, mainly pneumonia. In our study, lower respiratory tract infection was the most common high-risk source of infection, closely followed by primary bacteremia. Nevertheless, this finding should be interpreted with caution. As this issue was not one of the main purposes of our research, certain crucial variables, such as the duration of combined therapy, the onset time of this therapy, the antibiotic dosing, or how antibiotic treatment was administered (extended- or continuous-infusion or intermittent bolus) were not accounted for. Further studies are needed to clarify this question.

This study has several limitations. First, although cases were recorded prospectively, several data were obtained retrospectively and are therefore more vulnerable to potential bias. Second, the study was carried out in a single center and the results are not necessarily transferable to other settings with a different epidemiology. Third, although a sample of the included isolates was well characterized in previous studies, clonality and resistance mechanisms were not specifically investigated in all cases. Finally, some relevant variables such as the time until appropriate definitive antibiotic treatment or those related to combined antimicrobial therapy were not recorded, thus their impact on outcomes could have been potentially overlooked. On the other hand, this study has some highlighted strengths. It includes the largest published sample size of XDR *P. aeruginosa* bacteremia, eliminating the biases of many studies with small sample sizes, which reduce the statistical power to be able to draw reliable conclusions. Furthermore, a wide-ranging statistical analysis was performed to control for confounding variables, including a subanalysis in high-risk sources.

5. Conclusions {#sec5-jcm-09-00514}
==============

Our study identified severity at presentation, having a high-risk source of bacteremia, and inappropriate definitive antibiotic therapy as risk factors for mortality in patients with *P. aeruginosa* bacteremia. On the other hand, the XDR phenotype was not associated with poor prognosis. Decreased virulence in XDR strains, theoretical fitness costs, and a high prevalence of the less virulent ST175 high-risk clone at our institution may be among the reasons for these findings. Nevertheless, the mortality rate for *P. aeruginosa* bacteremia remains high in our cohort. Since antibiotic treatment is the only modifiable factor to try to improve outcome, strategies aimed at earlier identification of patients with risk factors for *P. aeruginosa* bacteremia should be implemented to avoid delays in the administration of effective antibiotic therapy, mainly in more severe patients and those with high-risk source bacteremia. Combined antimicrobial therapy should be considered in patients with bacteremia from high-risk sources.
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###### 

Baseline characteristics of the patients. Data are presented as *n* (%), unless otherwise specified. Abbreviations: m (median), IQR (interquartile range), XDR PA (extensively drug-resistant *Pseudomonas aeruginosa*), ICU (intensive care unit).

  ----------------------------------------------------------------------------------------------------
  Variable                                  All Episodes\   Non-XDR PA\      XDR PA\       *p*-Value
                                            (*n* = 382)     (*n* = 260)      (*n* = 122)   
  ----------------------------------------- --------------- ---------------- ------------- -----------
  Demographic information                                                                  

   Age in years, m (IQR)                    70.5 (60--78)   72 (60.25--78)   69 (59--76)   0.219

   Male sex                                 276 (72.3)      190 (73.1)       86 (70.5)     0.599

   Nosocomial acquisition                   244 (63.9)      143 (55)         101 (82.8)    \<0.001

  Underlying condition                                                                     

   Diabetes mellitus                        94 (24.6)       63 (24.2)        31 (25.4)     0.803

   Chronic obstructive pulmonary disease    82 (21.6)       53 (20.5)        29 (23.8)     0.475

   Cirrhosis                                28 (7.3)        18 (6.9)         10 (8.2)      0.656

   Hemodialysis                             25 (6.5)        18 (6.9)         7 (5.7)       0.662

   Hematologic malignancy                   58 (15.2)       31 (11.9)        27 (22.1)     0.010

   Solid tumor malignancy                   144 (37.7)      102 (39.2)       42 (34.4)     0.366

   Neutropenia                              70 (18.3)       51 (19.6)        19 (15.6)     0.341

  Charlson comorbidity index, m (IQR)       4 (2--6)        4 (2--6)         4 (3--6)      0.911

  McCabe score                                                                             

   Non-fatal McCabe                         107 (28)        73 (28.1)        34 (27.9)     0.966

   Rapidly fatal McCabe                     117 (30.6)      86 (33.1)        31 (25.4)     0.130

   Ultimately fatal McCabe                  158 (41.4)      101 (38.8)       57 (46.7)     0.145

  Source of infection                                                                      

   Catheter-related bloodstream infection   39 (10.2)       19 (7.3)         20 (16.4)     0.006

   Urinary tract infection                  116 (30.4)      74 (28.5)        42 (34.4)     0.237

   Respiratory infection                    95 (24.9)       67 (25.8)        28 (23)       0.552

   Skin and soft tissue infection           19 (5)          15 (5.8)         4 (3.3)       0.297

   Intraabdominal infection                 45 (11.8)       36 (13.8)        9 (7.4)       0.067

   Primary or Unknown                       62 (16.2)       45 (17.3)        17 (13.9)     0.404

   Other                                    6 (1.6)         4 (1.5)          2 (1.6)       1

   High-risk source                         227 (59.4)      167 (64.2)       60 (49.2)     0.005

   Low-risk source                          155 (40.6)      93 (35.8)        62 (50.8)     0.005

  Baseline illness severity                                                                

   Pitt score, m (IQR)                      2 (1--3)        2 (0--3)         2 (1--4)      0.017

   Pitt score ≥ 2                           206 (53.9)      133 (51.2)       73 (59.8)     0.112

   Septic shock                             103 (27)        65 (25)          38 (31.1)     0.207

   ICU admission                            96 (25.1)       61 (23.5)        35 (28.7)     0.272

  Antibiotic management                                                                    

   Appropriate empirical treatment          164 (42.9)      150 (57.7)       14 (11.5)     \<0.001

   Appropriate definitive treatment         332 (86.9)      227 (87.3)       105 (86.1)    0.737

   Combined antimicrobial therapy           150 (39.3)      87 (33.5)        63 (51.6)     0.001

  All-cause mortality                                                                      

   Day 14                                   89 (23.3)       59 (22.7)        30 (24.6)     0.682

   Day 30                                   118 (30.9)      77 (29.6)        41 (33.6)     0.431
  ----------------------------------------------------------------------------------------------------
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###### 

Univariate and multivariate Cox model of 14-day all-cause mortality. Data are presented as *n* (%), unless otherwise specified. Abbreviation: HR (hazard ratio), CI (confidence interval), m (median), IQR (interquartile range), ICU (intensive care unit), XDR PA (extensively drug-resistant *Pseudomonas aeruginosa*), BSI (bloodstream infection).

  ------------------------------------------------------------------------------------------------------------------------------------------
  Variables                                 Alive\          Death\          Crude HR\            *p*-Value   HR Multivariate\    *p*-Value
                                            (*n* = 293)     (*n* = 89)      (95% CI)                         (95% CI)            
  ----------------------------------------- --------------- --------------- -------------------- ----------- ------------------- -----------
  Demographic information                                                                                                        

   Age in years, m (IQR)                    70 (59.5--78)   71 (62.5--78)   1.01 (0.99--1.02)    0.252       1.01 (0.99--1.03)   0.119

   Male sex                                 209 (71.3)      67 (75.3)       1.17 (0.72--1.89)    0.518       1.12 (0.69--1.82)   0.645

   Nosocomial acquisition                   186 (63.5)      58 (65.2)       1.05 (0.69--1.4)     0.796                           

  Underlying condition                                                                                                           

   Diabetes mellitus                        73 (24.9)       21 (23.6)       0.96 (0.59--1.56)    0.858                           

   Chronic obstructive pulmonary disease    57 (19.6)       25 (28.1)       1.49 (0.94--2.37)    0.09                            

   Cirrhosis                                21 (7.2)        7 (7.9)         1.09 (0.51--2.37)    0.814                           

   Hemodialysis                             22 (7.5)        3 (3.4)         0.47 (0.15--1.48)    0.196                           

   Hematology malignancy                    42 (14.3)       16 (18)         1.22 (0.71--2.1)     0.465                           

   Solid tumor malignancy                   114 (38.9)      30 (33.7)       0.81 (0.52--1.26)    0.354                           

   Neutropenia                              51 (17.4)       19 (21.3)       1.22 (0.73--2.02)    0.445                           

  Charlson comorbidity index, m (IQR)       4 (2--6)        4 (2--6)        0.99 (0.93--1.07)    0.996                           

  McCabe score                                                              1.16 (0.89--1.51)    0.249                           

   Non-fatal McCabe                         83 (28.3)       24 (27)         0.98 (0.61--1.56)    0.932                           

   Rapidly fatal McCabe                     96 (32.8)       21 (23.6)       0.67 (0.41--1.09)    0.104                           

   Ultimately fatal McCabe                  114 (38.9)      44 (49.4)       1.41 (0.93--2.14)    0.105                           

  Origin of bacteremia                                                                                                           

   Catheter-related bloodstream infection   37 (12.6)       2 (2.2)         0.18 (0.05--0.74)    0.017                           

   Urinary tract infection                  103 (35.2)      13 (14.6)       0.36 (0.19--0.65)    0.001                           

   Respiratory infection                    60 (20.5)       35 (39.3)       2.17 (1.42--3.32)    \<0.001                         

   Skin and soft tissue infection           13 (4.4)        6 (6.7)         1.42 (0.62--3.25)    0.408                           

   Intraabdominal infection                 35 (11.9)       10 (11.2)       0.94 (0.49--1.81)    0.852                           

   Primary or Unknown                       40 (13.7)       22 (24.7)       1.84 (1.14--2.98)    0.013                           

   Other                                    5 (1.7)         1 (1.1)         0.69 (0.09--4.97)    0.715                           

   High-risk source                         153 (52.2)      74 (83.1)       3.85 (2.17--6.67)    \<0.001     3.07 (1.73--5.46)   \<0.001

   Low-risk source                          140 (47.8)      15 (16.9)       0.26 (0.15--0.46))   \<0.001                         

  Baseline illness severity                                                                                                      

   Pitt score, m (IQR)                      1 (0.5--2)      4 (1--4)        1.36 (1.24--1.49)    \<0.001     1.25 (1.12--1.38)   \<0.001

   Pitt score ≥ 2                           140 (47.8)      66 (74.2)       2.78 (1.73--4.48)    \<0.001                         

   Septic shock                             63 (21.5)       40 (44.9)       2.59 (1.71--3.95)    \<0.001     1.75 (1.12--2.75)   0.015

  ICU admission                             56 (19.1)       40 (44.9)       2.92 (1.92--4.44)    \<0.001                         

   Antibiotic management                                                                                                         

   Appropriate empirical treatment          126 (43)        38 (42.7)       0.99 (0.65--1.51)    0.968                           

   Appropriate definitive treatment         266 (90.8)      66 (74.2)       0.35 (0.22--0.57)    \<0.001     0.39 (0.24--0.62)   \<0.001

   Combined antimicrobial therapy           114 (38.9)      36 (40.4)       1.02 (0.67--1.88)    0.545                           

  XDR PA BSI                                92 (31.4)       30 (33.7)       1.02 (0.68--1.56)    0.915       1.07 (0.68--1.67)   0.777
  ------------------------------------------------------------------------------------------------------------------------------------------

jcm-09-00514-t003_Table 3

###### 

Univariate and multivariate Cox model of 30-day all-cause mortality. Data are presented as *n* (%), unless otherwise specified. Abbreviation: HR (hazard ratio), CI (confidence interval), m (median), IQR (interquartile range), ICU (intensive care unit), XDR PA (extensively drug-resistant *Pseudomonas aeruginosa*), BSI (bloodstream infection).

  -------------------------------------------------------------------------------------------------------------------------------------------
  Variables                                 Alive\           Death\           Crude HR\           *p*-Value   HR Multivariate\    *p*-Value
                                            (*n* = 264)      (*n* = 118)      (95% CI)                        (95% CI)            
  ----------------------------------------- ---------------- ---------------- ------------------- ----------- ------------------- -----------
  Demographic information                                                                                                         

   Age in years, m (IQR)                    70 (59--77.75)   72 (62.75--78)   1.01 (0.99--1.02)   0.159       1.01 (0.99--1.03)   0.052

   Male sex                                 185 (70.1)       91 (77.1)        1.32 (0.85--2.04)   0.208       1.25 (0.8--1.95)    0.321

   Nosocomial acquisition                   162 (61.4)       82 (69.5)        1.31 (0.88--1.94)   0.178                           

  Underlying condition                                                                                                            

   Diabetes mellitus                        66 (25)          28 (23.7)        0.95 (0.62--1.46)   0.828                           

   Chronic obstructive pulmonary disease    50 (19)          32 (27.4)        1.47 (0.98--2.21)   0.062       1.1 (0.7--1.73)     0.675

   Cirrhosis                                19 (7.2)         9 (7.6)          1.06 (0.54--2.08)   0.876                           

   Hemodialysis                             22 (8.3)         3 (2.5)          0.34 (0.11--1.06)   0.064       0.35 (1.01--1.15)   0.083

   Hematology malignancy                    38 (14.4)        20 (16.9)        1.15 (0.71--1.86)   0.575                           

   Solid tumor malignancy                   102 (38.6)       42 (35.6)        0.88 (0.6--1.28)    0.505                           

   Neutropenia                              48 (18.2)        22 (18.6)        1.03 (0.65--1.64)   0.884                           

  Charlson comorbidity index, m (IQR)       4 (2--6)         4 (2--6)         1.01 (0.95--1.07)   0.744                           

  McCabe score                                                                1.2 (0.96--1.51)    0.116                           

   Non-fatal McCabe                         77 (29.2)        30 (25.4)        0.89 (0.59--1.35)   0.596                           

   Rapidly fatal McCabe                     87 (33)          30 (25.4)        0.72 (0.48--1.09)   0.124                           

   Ultimately fatal McCabe                  100 (37.9)       58 (49.2)        1.43 (0.99--2.05)   0.005       1.29 (0.89--1.89)   0.178

  Origin of bacteremia                                                                                                            

   Catheter-related bloodstream infection   34 (12.9)        5 (4.2)          0.34 (0.14--0.83)   0.017                           

   Urinary tract infection                  96 (36.4)        20 (16.9)        0.41 (0.25--0.66)   \<0.001                         

   Respiratory infection                    49 (18.6)        46 (39)          2.25 (1.55--3.26)   \<0.001                         

   Skin and soft tissue infection           12 (4.5)         7 (5.9)          1.26 (0.58--2.69)   0.558                           

   Intraabdominal infection                 29 (11)          16 (13.6)        1.18 (0.69--1.99)   0.537                           

   Primary or Unknown                       39 (14.8)        23 (19.5)        1.38 (0.87--2.17)   0.165                           

   Other                                    5 (1.9)          1 (0.8)          0.51 (0.07--3.63)   0.500                           

   High-risk source                         134 (50.8)       93 (78.8)        3.03 (1.96--4.76)   \<0.001     2.49 (1.56--3.99)   \<0.001

   Low-risk source                          130 (49.2)       25 (21.2)        0.33 (0.21--0.51)   \<0.001                         

  Baseline illness severity                                                                                                       

   Pitt score, m (IQR)                      1 (0--2)         4 (1--4)         1.38 (1.28--1.49)   \<0.001     1.25 (1.13--1.37)   \<0.001

   Pitt score ≥ 2                           120 (45.5)       86 (72.9)        2.73 (1.82--4.1)    \<0.001                         

   Septic shock                             51 (19.3)        52 (44.1)        2.63 (1.83--3.79)   \<0.001     1.77 (1.18--2.65)   0.006

   ICU admission                            44 (16.7)        52 (44.1)        2.99 (2.08--4.3)    \<0.001                         

  Antibiotic management                                                                                                           

   Appropriate empirical treatment          114 (43.2)       50 (42.4)        0.98 (0.68--1.41)   0.899                           

   Appropriate definitive treatment         240 (90.9)       92 (78)          0.42 (0.27--0.65)   \<0.001     0.42 (0.27--0.66)   \<0.001

   Combined antimicrobial therapy           96 (36.4)        54 (45.8)        1.29 (0.9--1.87)    0.157                           

  XDR PA BSI                                81 (30.7)        41 (34.7)        1.13 (0.77--1.65)   0.535       1.14 (0.77--1.69)   0.504
  -------------------------------------------------------------------------------------------------------------------------------------------
